REG - EKF Diagnostics Hldg - Enzyme fermentation capacity expansion progress

EKF Diagnostics HoldingsAnnouncement

20/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230620:nRST2099Da&default-theme=true

RNS Number : 2099D  EKF Diagnostics Holdings PLC  20 June 2023

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Enzyme fermentation capacity expansion progress

 

Factory Acceptance Testing on largest 14,500L fermenter completed and on track
for delivery this month

Validation process on other fermenters remains on track for operational
activity from summer 2023

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics
business, announces that its Life Sciences division's new 14,500L enzyme
fermenter has successfully completed Factory Acceptance Testing. This will be
the Company's largest fermenter in its capacity expansion programme, and is
scheduled for delivery this month, with installation and validation to be
completed in Q3 2023.

 

In addition, and as planned, the validation process has begun for the new 65L,
300L, 1,500L, and 3,000L fermenters, which are now all on site in the Life
Sciences facility in South Bend, Indiana. This range of smaller fermenters,
remain on track to be operational and revenue generating over the summer.

 

Julian Baines, Executive Chair, commented: "Following the successful ISO
13485:2016 and 9001:2015 audits across both of our Life Science sites last
month, we're delighted that we continue to make good progress on our capacity
expansion plans. We remain on track to have all of our new fermentation
capacity in South Bend installed and validated towards the end of Q3 2023,
with all but the largest fermenter becoming operational over the summer."

 

 

 EKF Diagnostics Holdings plc                                 www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair / Marc Davies, CFO             Tel: +44 (0)29 2071 0570

 Singer Capital Markets (Nominated Adviser & Broker)                                        Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Oliver Platts

 Walbrook PR Limited               Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth  Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

·    Point-of-Care analysers in the key areas of Hematology and Diabetes,
as well as Central Laboratory products including clinical chemistry reagents,
analysers and centrifuges

 

·    Life Sciences services provide specialist manufacture of enzymes and
custom products for use in diagnostic, food and industrial applications, as
well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZGMVVLGGFZM